Evidence map›Paper›PMID 21537349›Full record

ReviewNature reviews. Nephrology2011

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

Juan F Navarro-González, Carmen Mora-Fernández, Mercedes Muros de Fuentes, Javier García-Pérez

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 528 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
528citing papers in PubMed, 6 pooled it
29.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01847313 phase3completedstarted 2013, after this paper: background citation

Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease

Ran2013Enrolled20Registered outcomes6Posted comparisons0ConditionsDiabetic Kidney DiseaseArmsliraglutide
PMID 20622169PMID 20002084PMID 22691169PMID 21744074PMID 18487229PMID 19238145PMID 19585513PMID 17167242PMID 23173142PMID 14675042PMID 15664230PMID 16177002other papers from this trial
Open the trial in the graph
NCT02035891 naunknown statusnot on this mapstarted 2013, after this paper: background citation

Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study

TypeinterventionalSponsorChongqing Medical UniversityRan2013 to 2023Enrolled160ConditionsDiabetic NephropathyArmscolchicine 0.5mg/d, placebo 0.5mg/d
3 · Its place in the literature

Who cites it

528 citing papers in PubMed, 6 syntheses or guidelines pooled it, 1,057 citations in OpenAlex.

  1. Pooled it
  2. The Role ofGenes · 2025
    Pooled it
  3. Impact of DPP-4 Inhibitors on Interleukin Levels in Type 2 Diabetes Mellitus.The Journal of clinical endocrinology and metabolism · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. A macrophage-endothelial cell axis in kidney diseases.International urology and nephrology · 2026
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

468 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Juan F Navarro-GonzálezNephrology Service, University Hospital Nuestra Señora de Candelaria, Carretera del Rosario, 145, 38010 Santa Cruz de Tenerife, Spain. jnavgon@gobiernodecanarias.org
Carmen Mora-Fernández
Mercedes Muros de Fuentes
Javier García-Pérez
Hospital Universitario Nuestra Señora de Candelaria · ESGobierno de Canarias · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many lines of evidence, ranging from in vitro experiments and pathological examinations to epidemiological studies, show that inflammation is a cardinal pathogenetic mechanism in diabetic nephropathy. Thus, modulation of inflammatory processes in the setting of diabetes mellitus is a matter of great interest for researchers today. The relationships between inflammation and the development and progression of diabetic nephropathy involve complex molecular networks and processes. This Review, therefore, focuses on key proinflammatory molecules and pathways implicated in the development and progression of diabetic nephropathy: the chemokines CCL2, CX3CL1 and CCL5 (also known as MCP-1, fractalkine and RANTES, respectively); the adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion protein 1, endothelial cell-selective adhesion molecule, E-selectin and α-actinin 4; the transcription factor nuclear factor κB; and the inflammatory cytokines IL-1, IL-6, IL-18 and tumor necrosis factor. Advances in the understanding of the roles that these inflammatory pathways have in the context of diabetic nephropathy will facilitate the discovery of new therapeutic targets. In the next few years, promising new therapeutic strategies based on anti-inflammatory effects could be successfully translated into clinical treatments for diabetic complications, including diabetic nephropathy.

Indexed as

Diabetic NephropathiesInflammationCell Adhesion MoleculesChemokinesCytokinesHumansSignal TransductionCell Adhesion MoleculesChemokinesCytokines

Identifiers

PMID21537349
OpenAlexW1996854381

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.